Trial Profile
Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1beta-blocking antibody canakinumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Feb 2011
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary) ; Influenza virus vaccine; Meningococcal vaccine conjugate
- Indications Influenza virus infections; Meningococcal infections; Rheumatoid arthritis
- Focus Pharmacodynamics
- Sponsors Novartis
- 05 Nov 2010 New trial record.